



# The Potential of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer From Mechanism to Action

**MONDAY, 8 AUGUST 2022 | 18:00 – 19:00 CET**

MESSE WIEN EXHIBITION & CONGRESS CENTER | MESSEPLATZ 1  
A-1021 VIENNA, AUSTRIA | **ROOM:** STRAUSS 3



## MODERATOR



**Hossein Borghaei, DO, MS**  
Professor, Department of  
Hematology/Oncology  
Chief, Division of Thoracic  
Medical Oncology  
The Gloria and Edmund M. Dunn  
Chair in Thoracic Oncology  
Fox Chase Cancer Center  
Philadelphia, Pennsylvania, United States

## PANELISTS



**Antonio Passaro, MD, PhD**  
Medical Oncologist  
Division of Thoracic Oncology  
IRCCS European Institute of Oncology  
Milan, Italy



**Ticiana Leal, MD**  
Associate Professor  
Department of Hematology and Oncology  
Director, Thoracic Medical Oncology  
Winship Cancer Institute  
Emory University  
Atlanta, Georgia, United States



For more information and to register, visit:  
**[www.medscape.org/symposium/nsclc-adc](http://www.medscape.org/symposium/nsclc-adc)**

Satellite CME Symposium by Medscape Oncology Global

This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

## AGENDA

**18:00**

### Welcome and Introduction

Hossein Borghaei, DO, MS

**18:03**

### *Mechanism of Action and Targets of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer*

Antonio Passaro, MD, PhD

**18:18**

### *Antibody-Drug Conjugates in Non-Small Cell Lung Cancer. What Do the Data Show?*

Hossein Borghaei, DO, MS

**18:35**

### *Antibody-Drug Conjugates in the Clinic: Challenges and Perspectives*

Ticiana Leal, MD

**18:50**

### Audience Q&A

All Faculty

**18:59**

### Concluding Remarks

Hossein Borghaei, DO, MS



Light snacks offered by Medscape

## TARGET AUDIENCE

This activity is intended for an international audience of hematology/oncology specialists, pathologists, pulmonologists, and other members of the oncology care team.

## LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

- Mechanism of action of antibody-drug conjugates (ADCs)
- Latest clinical trials investigating ADCs in non-small cell lung cancer (NSCLC)

Have greater competence related to

- Diagnosing molecular alterations that are amenable to treatment with ADCs

Demonstrate greater confidence in their

- Understanding of the implications of the latest clinical evidence for ADCs in NSCLC

## ACCREDITATION STATEMENT

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

**WebMD** Global



For more information and to register, visit:

[www.medscape.org/symposium/nsclc-adc](http://www.medscape.org/symposium/nsclc-adc)